Home / Positive Phase-1 Results Targeting the Liver X Receptor
NZCR was recently involved in promising Phase-1 research of a new drug targeting triglycerides and a liver condition called nonalcoholic steatohepatitis (NASH). Elevated triglyceride levels are relatively common and can be influenced by factors such as diet, genetics, physical activity, and overall health.
Biopharmaceutical Company, OrsoBio, developed the new experimental drug, TLC-2716, to treat people with high triglycerides and/or NASH by targeting the Liver X Receptor which helps control levels of fats such as triglycerides and cholesterol. NZCR’s Phase-1 trials tested the safety and efficacy of the drug on healthy people, a critical step before initiating Phase-2 testing on patients who have high triglycerides and liver fat.
The drug aims to reduce fats in the blood in multiple ways, such as stopping the creation of new fats, clearing out existing fats from the blood, and reducing how much fat the body absorbs from food. In tests prior to the human phase testing, TLC-2716 showed it could significantly improve the levels of both triglycerides and cholesterol and also decrease liver fat.
NZCR, which specialises in Phase-1 studies, undertook initial human testing of TLC-2716. The data from the Phase-1 studies, which tests the drug on healthy people, demonstrated dose-dependent improvements in the levels of triglycerides in the blood. Results found the drug was safe for people to take, with no major side effects identified. Based on these promising Phase 1 results, OrsoBio plans to move on to the Phase-2a stage of testing TLC-2716 in patients who have high triglycerides and liver fat, hoping to learn more about how well this drug works in real patients.
NZCR partners with global pharmaceutical and biotechnology companies from around the world and provides world-renowned, physician-led, early-phase research.
OrsoBio, focuses on developing medications for severe metabolic problems like obesity, diabetes, and liver-related diseases. TLC-2716 is considered a strong contender to help people dealing with high triglycerides and liver issues. If you’d like to learn more about OrsoBio or the drug TLC-2716, you can read the study details here or visit their website at www.orsobio.com.
New Zealand Clinical Research (NZCR) provides state of the art research facilities and the expertise to conduct complex early phase clinical research in healthy participant and patient populations.